ChrysCapital Growth Fund IX
IRR (Gross)
21.4%
Fund Type
Private Equity Fund
Fund Target Size
₹20,000 Cr
Fund Tenure
8 Years
Min. Commitment
₹5 Crores
Fund Structure
Close-Ended Limited Partnership
About the Fund
ChrysCapital Growth Fund IX is the ninth fund in India's most established domestic private equity franchise, targeting ₹20,000 Crore. The fund deploys growth equity tickets of ₹400–2,000 Crore in profitable, established Indian businesses with identifiable value creation pathways. Sector focus: financial services, healthcare, consumer, technology, and specialty manufacturing — areas where ChrysCapital has 25 years of proprietary network and deal-flow advantages.
Fund IX builds on $5 billion+ of cumulative investments across 130+ companies and eight prior funds, with iconic exits in Mphasis, HDFC Standard Life, and Jubilant Foodworks. The fund's 25-year institutional LP relationships with global pension funds, sovereign wealth funds, and university endowments provide high-quality, long-duration capital aligned with the growth equity investment mandate.
Fund Manager Details
Kunal Shroff
Managing Partner, ChrysCapital
20+ years in Indian private equity; IIT / Wharton pedigree; board director at 8+ portfolio companies
Kunal Shroff joined ChrysCapital in 2006 and has led investments across financial services, healthcare, and technology. He serves on the boards of multiple portfolio companies and leads ChrysCapital's governance professionalisation and management incentive alignment programmes. He is a Managing Partner overseeing Fund IX's investment committee.
Fund Details
SEBI AIF Registration
IN/AIF2/09-10/0015
Fund Category
Category II AIF – Private Equity Fund
Investment Ticket Size
₹400 Cr – ₹2,000 Cr
Investment Period
4 years
Extension Options
2 × 1-year extensions (66% LP consent)
Management Fee
2.0% p.a. during investment period; 1.5% thereafter
Hurdle Rate
8% p.a.
Carried Interest
20% above hurdle (whole-fund carry)
Fund Administrator
KFIN Technologies
General Partner
ChrysCapital Management Company
Tax Treatment
Pass-through under Sec 115UB; LTCG 12.5% on equity exits post 24 months
Interested in this fund?
Speak with our institutional advisory team for eligibility, documentation, and onboarding.